Recently, Kim et al. identified another methylation-independent activity of EZH2 in prostate cancer, by discovering that it activates AR gene transcription through direct occupancy of its promoter, in both androgen-dependent prostate cancer (ADPC) and CRPC [47]. Here, EZH2 is linked to prostate cancer.